BioSpace News Archive

Hansa Biopharma AB will publish its interim report for January-September 2022 at 8:00 CET on October 20, 2022.

Immuneering Corporation announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for IMM-1-104, paving the way for the company to initiate a Phase 1/2a clinical trial of this oral, once daily small molecule, in development for the treatment of advanced RAS mutant solid tumors.

e-therapeutics plc is pleased to announce a fundraise of £13.5 million before expenses by way of a subscription for new ordinary shares of 0.1p each (“Ordinary Shares”) in the Company (the “Subscription”) at a price of 20p per Ordinary Share by funds managed by M&G Investment Management Limited (“M&G”), an institutional investor and an existing shareholder of the Company.

PT Bio Farma , the holding company for state-owned pharmaceutical companies in Indonesia , is ready to produce 20 million doses of the IndoVac COVID-19 vaccine this year and 100 million doses by 2024.

Ainos today announced the results from its antiviral efficacy study in hamsters against the Omicron variant of SARS-CoV-2 (the “Study”).

Accuray Incorporated (NASDAQ: ARAY) announced today the company is expanding its global footprint with the introduction of its CyberKnife ® platform in Africa.

BiondVax Pharmaceuticals Ltd. announced the filing yesterday of a Registration Statement (“Form F-1") with the US Securities and Exchange Commission (“SEC”) for a firm commitment underwritten offering of BiondVax American Depositary Shares (“ADSs”).

Intercept Pharmaceuticals, Inc. today announced that REVERSE, a Phase 3 study evaluating the safety and efficacy of OCA in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).

Mersana Therapeutics, Inc. today announced the launch of Oncology FACETS : an educational platform for healthcare providers that will address clinically impactful topics in gynecologic oncology.

EnPlusOne Biosciences Launches Enzymatic RNA Synthesis Platform with $12 Million in Seed Financing.